Peptide does not mean unapproved.
FDA-APPROVED PRODUCTS EXIST
Approval attaches to a product and label.
Semaglutide
FDA approved in specific branded products and indications; compounded products are not FDA approved.
Tirzepatide
FDA approved in specific branded products and indications; compounded products are not FDA approved.
Tesamorelin
FDA approved only to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; not indicated for weight-loss management.
SS-31 / Elamipretide
FDA accelerated approval as Forzinity for Barth syndrome patients weighing at least 30 kg; other uses remain unapproved.
PT-141 / Bremelanotide
Bremelanotide is FDA approved as Vyleesi only for premenopausal women with acquired, generalized hypoactive sexual desire disorder; it is not indicated for men, postmenopausal women, or sexual performance enhancement.
UNAPPROVED OR INVESTIGATIONAL
Research is not regulatory review.
BPC-157
Not FDA approved; FDA identifies important compounding safety and characterization concerns.
Retatrutide
Investigational and not FDA approved; FDA states retatrutide cannot be used in compounding under federal law.
MOTS-c
Not FDA approved; FDA reports no identified human exposure data for drug products containing MOTS-c.
TB-500
Not FDA approved; product identity and peptide-related impurities are material uncertainties.
Ipamorelin
No FDA-approved drug product; FDA identifies significant safety and characterization concerns for compounding.
Sermorelin
No current FDA-approved drug product identified in the August 2026 source snapshot.
CJC-1295
No FDA-approved drug product.
KPV
No FDA-approved drug product; FDA reports no identified human exposure data for compounded KPV products and insufficient safety information.
GHK-Cu
No FDA-approved GHK-Cu drug product identified; FDA has listed GHK-Cu among bulk substances considered by its compounding advisory process.
Thymosin Alpha-1
No FDA-approved thymosin alpha-1 drug product identified in the August 2026 source snapshot; products are used in some countries outside the United States.
Thymosin Beta-4
No FDA-approved thymosin beta-4 drug product identified in the August 2026 source snapshot.
LL-37
No FDA-approved LL-37 drug product; FDA reports insufficient human safety information for compounded LL-37 products.
AOD-9604
No FDA-approved AOD-9604 drug product; FDA identifies limited safety information and potential concerns for compounded use.
Epitalon
No FDA-approved Epitalon drug product; FDA enforcement records have described Epitalon products as unapproved new drugs.
Semax
No FDA-approved Semax drug product; FDA identifies immunogenicity and peptide-impurity concerns for compounded Semax products.
Selank
No FDA-approved Selank drug product; FDA identifies immunogenicity and peptide-impurity concerns for compounded Selank acetate products.
DSIP
No FDA-approved DSIP drug product; FDA enforcement records have described DSIP products as unapproved new drugs.
Melanotan II
No FDA-approved Melanotan II drug product; FDA identifies safety and immunogenicity concerns and has warned about illegal marketing.
Glutathione
No FDA-approved injectable glutathione drug product identified; FDA has reported adverse events linked to contaminated compounded sterile glutathione.